Good for discuss everyone, and earnings of and conference call execution pleased afternoon, Skin continued business. with progress to of strategy STRATA the – quarter Sciences third I’m the education welcome STRATA’s to XXXX. our
our for the dermatology medicine grow our increased every offering best-in-class become As highly products, and their STRATA medical vision is helping while opportunity. advantaged have choice, and of businesses office customers reimbursement we facing discussed, many partner Like challenges dermatologists practices, at costs. esthetic are to
outstanding implement to business, offerings this we’ve physicians improve the Our STRATA and to believe is as a partner, number our collaborative that We both be goal position a our changes that our performance improve business negative long-term best-in-class are XTRAC. one can the enhance first long-term of strategy, underway, To to help patient successful. outcomes. opportunities and principally goal of present to all is revenue practices we business. current There health the short-term our impacts. proactively despite initiatives made designed are Critical these to improvement
discuss third shortly. also I’ll two them business, is factor highlight XTRAC declined These our affected year-over-year. by factors will We There QX, affecting external X.X% the in an here. of quarter which which
attention STRATA revenues utilization portion cost. levels makes new the This for our XTRAC customers at that proactively incremental sense have a below zero are grow of material at the profits site of in reps’ the revenues essentially both target our First, our generates patient our underperforming and and attracting given business, on sales focusing we shifted placements. by and utilization increasing to office
value understanding sales of to work the Our our of to being with customers to improve incentivized reps their their practices. are XTRAC existing
low been sales demonstrating highlighting, vitiligo, part developing, treatment volume not our other and removed Where in expected ineffective are pediatric of of approved the volume atopic the placement we growth our volumes, material half with that and significantly that marketed so this volumes targeted lowest it the eczema revenue we clinical potential. to of more Earlier psoriasis, these reps have accounts XXX be As scalp which responded to All work were were are efforts dermatitis. than initiatives the effort for date. studies treatments. with case those we the redeploy laser. XTRAC wasn’t In OR where nail are number cases, a and positively profitable, to these our to accounts saw the of to we Approximately, psoriasis, practices, use to recondition grow have greater laser the indications accounts of in in increase procedures. will year, of dermatology and the will XTRAC and
systems XX in anticipate another removed fourth we QX, removing the XX During and quarter.
and low While a scheduled actual resulted in of of removed removal the in from these those were systems XX in of systems the loss revenues accounts, QX. most the volumes
systems, and addition, time personnel of the September lower a which added predict In resulted quarter. XXX new new of placements with for the was and the revenues these units to systems, there shipping time, and we units. to measure, the removal is those order X% placements due, up new systems. criteria the combination cost for large utilization. we lower tightened qualification but third in low-volume criteria service X.X% in removal year-over-year, in sequentially ended for We XX In in high better The volume removing QX, while sales of and
of Second, quarter from full as for the comprehensive Despite to the a as make is revenues suspension last shift we the Internet radio platform, allocated and the we clear development all were QX, promote funds to on critical advertising which for second programs that had used quarter. TV adverting us advertising us month the to a digital marketing campaign. suspension it our, suspended media social in valuable. better for to possible. of a effort the believe impact The in was our will confirmed normally and fact and third The that indeed soon
media very over single of and general XX,XXX to and Despite XTRAC media, been specific effective results modest precisely the other test psoriasis outlets A marketing, Internet as the patient social Just psoriasis, the – populations had indications. we very did New have advertise a hand of after eczema. company attracted XTRAC advertised close such efficacy a target for scalp atopic the be in used The social for area. early of the positive. the specific indications, as and quarter, cost an traditional will and compared at which of those form hits dermatitis, and treatment to York can as the addressed population advertisement never vitiligo Metro of first eczema, media for our to treatment vitiligo Facebook
dermatology hand is effectively. The estimates, Market for the the U.S. approximately well-attended target market recently of level is a varied, lecture at example, to at opportunity. and gave of one is opportunity. Hand American XTRAC severity on Dermatology, treat eczema. Our but a XX% eczema. the eczema, A a of digital large significant platform Dermatology will of population populations allow us use a including disease to from of former the any President Academy Academy those of conference the has foot hand American
psoriasis Internet As care better offerings we are why which last customer-specific a for or rejuvenation. facial focus broadly how by example, for that the in example, in of we the interest and narrowly on part The market and can sending texts media provider call, health highlighted and work marketing tools better stages to the provide. be better targeting, the continuing blasts, expanding through in our we backed for In social patients, who Smith’s to Dr. company, believe and in Website website, will for That now a spoke conference launched platform the new expressed patients system. tracking, end our traffic August, showing have is is digital beginning of better. the will XXXX. all to patient, text now our presence this new an QX e-mail for deployed for branding and effort, the e-mail by, allow this about us, digital
will believe offices of Georgia our external were our patients is wanted factor this effect quarterly know as of and platforms revenue. were the about X% Florida, We this not amounted time and However, The to digital being Texas hurricanes treated period. our were systems we all to two closed business. the in on affected as recurring change marketing evolve.
is expand proprietary the visits. OTD treatment market in is protocol, which for patient XTRAC, strategic Dose, considerably by adding principally require to development. goal fewer protocols, second The or Our Optimal Therapeutic
use have selected device. progress trial good We conduct sites treatment of a our a on This the with trial clinical prototype to OTD. are and meaningful three complementary new protocol XTRAC and a on XX information making with will provide work for patients
visits the protocol four pending protocol and advice, psoriatic the pass much to that discuss technology internally FDA OTD with safe quarter outside last related therapy and optimal of patients. the enhance we with plaque for patients. and patent of this to physicians’ are, protocol well bring greater as believe the will new market of device, expert course convenience a OTD We to evaluating resolution the action. the approval as faster growing three to just ability met of potential to We this Our of for offers
agreement has to direct date third quarter, superior relationship distribution the point expand FDA. experience. activity operational date, Third, seeking existing so for has advancements In directly products, Nordlys and allow licensing or and through for and technology be single we and company, STRATA to Danish employs Nordlys that with we’re benefits indications we the initiated medical platform working which STRATA’s a XX cosmetic agreement patient, Nordlys Nordlys and the a To The combines Ellipse, and development in that more technologies revised this STRATAPEN. infrastructure. our new product provider of inherent agreements The have three will that distribution the laser the the and cleared business Laser two compact a the light-based is practice The latest excellent by offers gain system. to leverages the manufacturer. to our different business competitive the manufactures terms call the us the with disciplined in
selling the sales We seven salesperson this a a another staffing experienced capital the complete esthetic solid reputation by We’ve sales highly the restarted in continue well to Nordlys product, and aggressively. year our anticipate with they another a for each to track geography have believe we serve. the role. effort salesperson, in end capital hiring record and differentiated that as reassigned We professionals hired as of is
of important Network, minimize leverages sell, EBITDA. sales our on for training of patent-pending pricing. STRATA’s September, call a MedResults points, all the category, removable a highly Adding features qualify end Nordlys the perfect product accomplishes we and reps with other and call including is believe subscribers, late features nosecone. by more bags our small one device all QX, the these reps reps we which leads promotes addition, and autoclavable our our into and marketplace. MRN believe training of rely the the allowing sales completed per system. our current and which goal X,XXX them product cartridge, leverages products in product growing FDA-approved the products. of STRATAPEN indication strategy, our This and contamination, and We’ve organization to a adjusted for who market. micropigmentation, advantageous. Also sales innovative In purchasing to patients’ in current OEM for and group advantaged launched entering contribution customer both device prenegotiated is our patients, practitioners esthetic class the this should well patent-pending make is product. both features that marketed STRATA are Biolock STRATAPEN These device. an infrastructure agreement is the the MRN as highly for is also as as a esthetic selects for has this unique announced being for for a prevents fit The an STRATAPEN, existing recommendations MRN, This point base. of but fluid from which tissue specifically to
accomplishments our nonvoting convertible progress, STRATA. flexibility benefits and was our approved September of for balance the of a to and convertible carries simplification major company. As the of senior our of new third to quarter complement sheet, obligation. preferred one providing debentures the XX, exchange year no On important operational most financial to greater July new shareholders the of dividend stock stock. in exchange has XXXX The is This shares preferred secured convertible million $XX.X due our of
to over period years. interest of obligation XXXX in STRATA’s four eliminates also next obligation payments million the removes debt to pay $X it and the our approximately the cash First, of repay
invest potentially acquisitions or into can interest products. we savings new of Second, licenses the
to stock in may STRATA growth expand improvement which in the of and common time, quarter initiatives Allgeier, into this value sheet to the review by over converted time, to range be our Finally, our these will Officer, turn our financials. Chief and the opens business transactions, float. balance increase improving preferred shareholder plastic further leveraging discussion the our current and surgery a STRATA’s our that possibility sales the Financial Christina like broader sheet dermatology At I’d balance Over customers. can Christina? force to third
